Aclarion, Inc. (ACON)
- Previous Close
0.3927 - Open
0.3250 - Bid 0.2474 x 200
- Ask 0.4163 x 200
- Day's Range
0.3200 - 0.3635 - 52 Week Range
0.2670 - 25.6000 - Volume
3,504,693 - Avg. Volume
2,788,555 - Market Cap (intraday)
2.411M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-705.6000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.50
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
www.aclarion.com4
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ACON
Performance Overview: ACON
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACON
Valuation Measures
Market Cap
2.41M
Enterprise Value
2.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.03
Price/Book (mrq)
--
Enterprise Value/Revenue
33.36
Enterprise Value/EBITDA
-0.61
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-113.41%
Return on Equity (ttm)
-655.74%
Revenue (ttm)
75.4k
Net Income Avi to Common (ttm)
-4.91M
Diluted EPS (ttm)
-705.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.1M